Nov 06, 2025 4:02pm EST Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Oct 31, 2025 8:00am EDT Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
Oct 30, 2025 7:30am EDT Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
Sep 10, 2025 7:47am EDT Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
Sep 02, 2025 7:47am EDT Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 12, 2025 7:47am EDT Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Aug 07, 2025 4:06pm EDT Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 04, 2025 7:47am EDT Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025
Jun 30, 2025 8:00am EDT Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)
